section epub:type=”chapter” id=”c0038″ role=”doc-chapter”> Jennifer E. Stokes Cats are affected by many vector-borne pathogens (VBP) carried by fleas, ticks, and sand flies. Common VBPs in cats include Bartonella spp., hemoplasmas, Borrelia burgdorferi, Anaplasma phagocytophilum, and Cytauxzoon felis among others. Like dogs, cats may be coinfected with more than one VBP and because the clinical signs of some diseases caused by VBP overlap, it makes sense to assess the patient for more than one VBP using pathogen panels. This chapter discusses selected VBP in cats that are not covered in other chapters. Bartonellosis; Bartonella spp.; Anaplasma phagocytophilum; anaplasmosis; Cytauxzoon felis; ehrlichiosis; Ehrlichia spp.; borreliosis; Borrelia burgdorferi; coxiellosis; Coxiella burnetii; sand fly; flea; tick; Rikettsia spp.; leishmaniasis; Leishmania spp.; babesiosis; Babesia spp.; hepatozoonosis; Hepatozoon spp.; vector-borne diseases Control of ectoparasites is important for preventing diseases caused by VBP in cats and in people. In most countries, a variety of products are available with efficacy against one or more ectoparasites. In the United States, the Companion Animal Parasite Council*1 recommends use of flea and tick control products year-round in dogs and cats. Likewise, the European Scientific Counsel on Companion Animal Parasites†2 recommends flea protection year-round and tick protection during the seasons when ticks are active. Veterinarians and cat owners may not appreciate the need for ectoparasite control for more than just the warm months and may not understand that even cats living indoors may need protection. For example, in a large survey of ticks collected from cats in the United States, they were collected every month of the year, including the winter, underscoring the need for multiseason tick protection.1 The effectiveness of ectoparasite preventive products depends on the efficacy of the active ingredient and adherence of the pet owner to administration instructions. Studies of purchase and use of ectoparasite preventive products by cat owners show that too many owned cats do not receive appropriate protection. In a survey of 213 dog and cat owners in Lisbon, about 63% of cats were treated with ectoparasites but usually at infrequent intervals.2 A retrospective survey of over 1200 cats at a veterinary teaching hospital in the United States found that only 38% were receiving ectoparasiticides and only 18% received treatment year-round.3 A survey of purchase records from over 114,000 cat owners in the United States found that most bought <6 months of protection during the year, with 61% to 75% purchasing only 1 to 3 months, depending on the product.4 Clearly, adherence to recommendations often falls far short of what is necessary to protect cats from VBP. This chapter discusses selected VBP in cats that are not covered in other chapters. Additional resources are found in Rickettsia are obligate intracellular gram-negative bacteria that are transmitted by an arthropod vector, typically a tick or flea. Pathogenicity in people and dogs is well understood, but less is known in cats. Ehrlichia spp. primarily infect leukocytes, while Anaplasma spp. typically infect erythrocytes, endothelial cells, platelets, and leukocytes. Although rickettsial infections may be an emerging problem in cats, dogs appear more susceptible to disease. Ehrlichia canis and A. phagocytophilum are the primary rickettsial agents that cause disease in cats. Rickettsia felis, Rickettsia asembonensis, and Rickettsia typhi have been isolated from cat fleas and/or cats, but the clinical significance of these species is unknown. The zoonotic potential for cat fleas to transmit rickettsial organisms should be suspected, further emphasizing the need for routine ectoparasite control for all cats.5–7 Vectors for E. canis include Rhipicephalus sanguineus and Dermacentor variabilis ticks. In a report of three cats in Kenya with anemia due to ehrlichiosis, all were parasitized by Haemaphysalis leachi (known as the yellow dog tick or African dog tick).8 Clinical ehrlichiosis in dogs has been well-recognized and understood for decades. Although the first evidence of naturally transmitted ehrlichiosis in cats was described in 1986, our understanding of the disease in cats and which Ehrlichia spp. are infective is incomplete. Feline ehrlichiosis has been recognized in countries such as the United States, France, Sweden, Kenya, Brazil, and Thailand.9 The pathogenesis of feline ehrlichiosis is thought to be similar to that of ehrlichiosis in dogs. Key features of feline ehrlichiosis are in Box 38.1. The primary risk factor for feline ehrlichiosis is exposure to vectors. Affected cats range from 1 to 14 years of age, although most are young.10 There is no obvious sex predisposition and most affected cats are domestic shorthairs.9 Although feline ehrlichiosis occurs worldwide, there is a poor knowledge of prevalence. A study in Brazil found a prevalence of 8.6% in 93 cats with PCR testing, while 45% of those cats were seropositive.11 A seroprevalence of 17.9% was found in urban stray and pet cats in Spain.12 However, seroprevalence studies may overestimate prevalence as antibodies from exposure to other pathogens (e.g., Bartonella henselae13 and other Neorickettisa and Anaplasma spp.14) may cross-react with E. canis antigens. Owners may or may not report a history of tick exposure and a history of purchasing ectoparasite preventatives does not rule out ehrlichiosis. Clinical signs are nonspecific and include anorexia, lethargy, and weight loss. In a report of three cats, physical examination abnormalities thought to be secondary to ehrlichiosis included fever, splenomegaly, joint pain, lameness, myalgia, lymphadenopathy, pallor, and petechial hemorrhage.9 Laboratory abnormalities in cats with evidence of ehrlichiosis (based on detecting E. canis-like DNA) include thrombocytopenia, severe bicytopenia, marked pancytopenia, marked neutrophilic leukocytosis (with or without a left shift), non-regenerative anemia, positive anti-nuclear antibody titer, and polyclonal hyperglobulinemia.9,11,15 In a report of three cases, one cat was diagnosed with neutrophilic polyarthritis and a pancytopenic cat had bone marrow cytology changes consistent with myelodysplasia or myeloid leukemia.9 A cat with anemia and thrombocytopenia had cytologic and histopathologic bone marrow changes that included marked erythroid and megakaryotic hypoplasia. Lymph node cytology findings included reactive hyperplasia and pyogranulomatous inflammation. All three cases were complex and all physical and laboratory abnormalities could not be attributed definitively to E. canis-like infection, although most have been reported in dogs with ehrlichiosis. A combination of PCR, serology, and close examination of a blood smear for morulae (Fig. 38.1) are recommended in cats when a vector-borne illness such as ehrlichiosis is suspected. Identification of morulae in feline monocytes should always lead to submission of blood for PCR evaluation for VBP. Unfortunately, even in severely ill animals, intracellular morulae are uncommon. When performed by experienced reference laboratories, PCR is sensitive for diagnosis of infection in patients that are rickettsemic and a positive result is consistent with a current infection. However, a negative PCR result does not rule out ehrlichiosis. Negative results are more likely in chronic infections or if patients have received prior antibiotic therapy, particularly tetracyclines. Use of serology alone for diagnosis of E. canis in cats is not recommended. The prevalence of antibodies in sick and healthy cats is unknown. A cat with ehrlichiosis may be seronegative in the acute stages of infection, so measurement of paired samples collected about 4 weeks apart is appropriate. Cross-reactivity between Ehrlichia spp. and Anaplasma spp. can occur. Point-of-care screening tests used in dogs to test for E. canis and A. phagocytophilum can also be used in cats as the assays are not species-specific. Oral doxycycline (10 mg/kg/day for 28 days) is considered the treatment of choice for ehrlichiosis in dogs and likely in cats as well. The prognosis for cats treated for E. canis infection is unknown due to the scarcity of confirmed cases. Based on the response in infected dogs, treatment is likely successful in most cases. It is unknown if cats are susceptible to persistent or recurrent infections. Anaplasma phagocytophilum is the causative agent of anaplasmosis in dogs, ruminants, horses, and people. Cats can develop disease after experimental inoculation as well as natural transmission. Ixodes spp. ticks are vectors for transmission of A. phagocytophilum to dogs and are likely vectors for cats as well (Fig. 38.2).16 It is unknown if other modes of transmission, such as the ingestion of or contact with A. phagocytophilum–infected rodents, occur in cats. The pathogenesis of feline anaplasmosis is likely similar to that in other species. Transmission occurs within 24 to 48 hours of tick attachment and the organism infects neutrophils, leading to the formation of intracellular morulae. The primary risk factor for infection is likely exposure to the vectors that transmit A. phagocytophilum. In the United States, anaplasmosis has only been diagnosed in cats living in the Northeast; the tick vector is Ixodes scapularis.17 In Europe, the vector for A. phagocytophilum is Ixodes ricinus. Most cats with a PCR-based diagnosis have access to outdoors; use of ectoparasite preventatives does not prevent infection in all cats. Anaplasmosis has been diagnosed in cats from 4 months to 13 years of age, with a median age of 2 years.17 There is no sex or breed predisposition. Anaplasma phagocytophilum has been detected in cats in many countries, such as the United States, some European countries, Korea, and Brazil. However, the prevalence of exposure to A. phagocytophilum is higher than the prevalence of clinical disease. 17 Owners may or may not report exposure to ticks. Historical findings are often nonspecific. The most common clinical signs are lethargy and fever.17–19 Clinical signs are usually acute and may occur 3 days to 3 weeks after tick removal. Duration of clinical signs is 1 to 14 days. Physical examination abnormalities include joint swelling and pain, conjunctivitis, ocular discharge, abdominal discomfort, ataxia, and pallor.17–19 Tachypnea and increased lung sounds have also been described. The most common laboratory abnormalities in affected cats are lymphopenia, thrombocytopenia, morulae in neutrophils, neutropenia, and leukopenia.17–19 The use of Romanowsky or Wright-Giemsa stains may facilitate cytologic confirmation of intraneutrophilic inclusions and morulae. The organism may appear as a single inclusion approximately 0.54 to 1.3 microns in size or as morulae (a colony of organisms) 1.5 to 5 microns in size. The presence of morulae is variable and uncommonly seen in cats with anaplasmosis. Detection of A. phagocytophilum DNA by PCR is now the primary diagnostic method in cats. If a vector-borne disease is suspected, the patient should be tested for additional organisms that can be transmitted by the same vector. For example, Ixodes spp. ticks are vectors for Bartonella burgdorferi and A. phagocytophilum. Concurrent infections in cats with anaplasmosis have included feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), Mycoplasma haemominutum, B. henselae, and Bartonella koehlerae.17,20 Diagnosis via measurement of A. phagocytophilum antibodies alone is not recommended as cats in endemic areas may be seropositive without clinical disease. Additionally, patients may be seronegative during the acute stage of the disease. If titers are measured, they should be repeated in 4 weeks; a fourfold increase is consistent with disease. Anaplasma phagocytophilum is poorly sensitive or resistant to many antibiotics, including beta-lactams, macrolides, lincosamides, sulfonamides, carbapenem, aminoglycosides, and chloramphenicol. Tetracyclines are considered the first line of therapy; treatment protocols include: In published cases, all cats had clinical improvement after administration of tetracycline or doxycycline, many within 48 hours.17–19 However, some cats will continue to test PCR-positive for weeks or months.21 Some clinicians also administer short-term corticosteroids (e.g., subcutaneous dexamethasone, 0.2 mg/kg/day, for 3 days) as an immune-mediated mechanism may contribute to thrombocytopenia. Consistent administration of ectoparasite preventatives year-round is recommended for all cats living in endemic areas. Borreliosis (Lyme disease) is caused by bacteria in the B. burgdorferi complex found in much of the world, including the United States (especially the upper Midwest, Northeast, mid-Atlantic, and parts of northern California) and Europe (Fig. 38.3). This bacterium can infect a range of mammals, including cats. In the United States and Europe, borreliosis is the most common vector-borne illness of humans. In North America, B. burgdorferi is transmitted by Ixodes scapularis and Ixodes pacificus ticks. In other countries, tick species such as Ixodes ricinus, Ixodes hexagonus, and Ixodes persulcatus are involved in transmission. Wildlife reservoirs for B. burgdorferi include mice, voles, shrews, chipmunks, squirrels, hedgehogs, and many bird species. Ticks acquire B. burgdorferi when they feed on a reservoir host and transmit the infection when they attach to a cat to feed. In endemic areas, cats are sometimes seropositive for B. burgdorferi, and the infection can be transmitted experimentally.22,23
Selected Vector-Borne Diseases
Abstract
Keywords
INTRODUCTION
e-Box 38.1.
BACTERIA
Rickettsia
Ehrlichiosis
RISK FACTORS AND PREVALENCE
MEDICAL HISTORY, CLINICAL SIGNS, AND PHYSICAL EXAMINATION FINDINGS
DIAGNOSIS
TREATMENT AND PROGNOSIS
Anaplasmosis
RISK FACTORS AND PREVALENCE
MEDICAL HISTORY, CLINICAL SIGNS, AND PHYSICAL EXAMINATION FINDINGS
DIAGNOSIS
TREATMENT AND PROGNOSIS
Other Bacteria
Borreliosis
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree